Methods and compositions for the treatment or prevention of immune disorders using combination therapy
OwnerChristopher C. Fraser, Wayne Hancockinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of suppressing immune disorders such as allograft rejection in a patient by a combination of inhibition of the binding of LIGHT to HVEM and immunosuppressive therapy. Various therapeutic regimens are provided. The present invention further provides kits and pharmaceutical compositions useful in the present methods.
Claims63
A method of treating or preventing an immune disorder in a patient, comprising administering to the patient (i) an HVEM-LIGHT inhibitor;
- and (ii) an immunosuppressive agent, in amounts effective for treating or preventing the immune disorder.
A pharmaceutical composition comprising:
- a. an HVEM-LIGHT inhibitor;
- b. an immunosuppressive agent;
- and
- c. a pharmaceutically acceptable carrier;
- wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are present in amounts effective to prevent or treat allograft rejection.
A kit comprising in one or more containers:
- a. HVEM-LIGHT inhibitor;
- b. an immunosuppressive agent;
- and
- c. instructions for the use of the HVEM-LIGHT inhibitor and the immunosuppressive agent in the prevention or treatment of allograft rejection.
An isolated nucleic acid molecule selected from the group consisting of:
- a. a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:3 or a complement thereof as determined using the BLAST algorithm;
- b. a nucleic acid molecule comprising at least 15 nucleotide residues and having a nucleotide sequence identical to at least 15 consecutive nucleotide residues of residues 1-424 of SEQ ID NO:3 or a complement thereof;
- c. a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:4;
- d. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NO:4, wherein the fragment comprises at least 12 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4;
- and
- e. a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:4, wherein the nucleic acid molecule hybridizes under stringent conditions with a nucleic acid molecule consisting of the nucleotide sequence of any of residues 1-424 of SEQ ID NO:3 or a complement thereof.
The isolated nucleic acid molecule of claim 44, wherein the fragment comprises at least 15 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.
An isolated polypeptide selected from the group consisting of:
- a. a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:4;
- wherein the fragment comprises at least 12 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4;
- b. a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO:4, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of residues 1-424 of SEQ ID NO:3 or a complement thereof under stringent conditions;
- and
- c. a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid consisting of residues 1-424 of SEQ ID NO:3 or a complement thereof as determined using the BLAST algorithm.
Dependencies are inferred from the claim text.